Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Prime Medicine Inc
The investment seeks to provide long-term total return. Under normal market conditions, the fund will seek to achieve its investment objective by investing at least 80% of its net assets (including investment borrowings) in U.S. and non-U.S. exchange-traded real estate securities, which includes real estate investment trusts ("REITs"), real estate operating companies ("REOCs") and common stocks or depositary receipts of companies primarily engaged in the real estate industry (collectively, "Real Estate Securities"). It is non-diversified.
IPO Date: October 20, 2022
Sector: Healthcare
Industry: Biotech
Market Cap: $663.18M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.30 | 3.98%
Avg Daily Range (30 D): $0.16 | 4.22%
Avg Daily Range (90 D): $0.14 | 5.49%
Institutional Daily Volume
Avg Daily Volume: .98M
Avg Daily Volume (30 D): 3.26M
Avg Daily Volume (90 D): 3.35M
Trade Size
Avg Trade Size (Sh.): 135
Avg Trade Size (Sh.) (30 D): 176
Avg Trade Size (Sh.) (90 D): 211
Institutional Trades
Total Inst.Trades: 192
Avg Inst. Trade: $1.9M
Avg Inst. Trade (30 D): $1.02M
Avg Inst. Trade (90 D): $1M
Avg Inst. Trade Volume: .23M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.7M
Avg Closing Trade (30 D): $1.04M
Avg Closing Trade (90 D): $.99M
Avg Closing Volume: 315.89K
   
News
Aug 7, 2025 @ 4:27 PM
PRME Revenue Misses by 73%
Source: Jesterai
Jul 31, 2025 @ 1:33 AM
Prime Medicine Announces Pricing of Public Offerin...
Source: Gregory Dearborn
Mar 19, 2025 @ 6:56 PM
Why Prime Medicine Stock Is Soaring Today
Source: Johnny Rice
Mar 18, 2025 @ 11:00 AM
Prime Medicine Unveils Program for the Treatment o...
Source: N/A
Nov 12, 2024 @ 9:00 PM
Prime Medicine Reports Third Quarter 2024 Financia...
Source: Prime Medicine, Inc.
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $-.41 $-.4 $-.31
Diluted EPS $-.41 $-.4 $-.31
Revenue $ 1.12M $ 1.45M $ 2.18M
Gross Profit $ $ $
Net Income / Loss $ -52.59M $ -51.89M $ -42.28M
Operating Income / Loss $ -53.38M $ -52.39M $ -44.22M
Cost of Revenue $ $ $
Net Cash Flow $ -38.44M $ -90.6M $ 64.5M
PE Ratio